RNS Number : 5854F RTW Biotech Opportunities Ltd

31 October 2025



## LEI: 549300Q7EXQQH6KF7Z84

31 October 2025

### **RTW Biotech Opportunities Ltd**

#### Royalty Funding Agreement with Savara Inc.

- Savara announces 75m funding agreement with funds managed by RTW
- Subject to FDA approval of MOLBREEVI, a treatment for rare lung disease
- RTW Bio will participate through its investment in 4010 Royalty Fund

RTW Biotech Opportunities Ltd (the "Company"), the London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to note the announcement by **Savara, Inc.** ("Savara" Nasdaq: **SVRA**) that it has entered into a 75 million royalty funding agreement with funds managed by RTW Investments, LP. RTW Bio will participate in this investment through its commitment to the RTW-managed 4010 Royalty Fund. Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases.

The funding is subject to FDA approval of Savara's lead program, MOLBREEVI, a treatment in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP), a rare disease characterised by the abnormal build-up of surfactant in the alveoli of the lungs. Assuming FDA approval, the funding will support the U.S. launch and further commercialisation of MOLBREEVI, which would be the first approved drug for autoimmune PAP.

Rod Wong, CIO of RTW Investments, said, "The pivotal clinical trial demonstrated the potential of MOLBREEVI to treat autoimmune PAP and this investment reflects our confidence in Savara and the strong commercial potential of the therapy. We are proud to partner with the Savara management team and look forward to supporting their efforts to bring this meaningful treatment to patients."

+44 (0)20 7959 6362

biotechopportunities@rtwfunds.com

+44 (0)7984 184 461 / lucy@cadarncapital.com

+44 (0)7368 883 211 / david@cadarncapital.com

Savara's announcement can be found here.

# Enquiries:

RTW Investments, LP - Investment Manager

Oliver Kenyon Woody Stileman

Krisha McCune (Investor Relations)

Cadarn Capital - PR & IR Partner

Lucy Clark (PR)
David Harris (Distribution)

Deutsche Numis - Joint Corporate Broker +44 (0)20 7260 1000

Freddie Barnfield Nathan Brown

**BofA Securities - Joint Corporate Broker** 

Edward Peel Alex Penney +44 (0)20 7628 1000

+44 (0)1481 703 100

Altum (Guernsey) Limited Joanna Duquemin Nicolle

Sadie Morrison

# About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the website at <a href="www.rtwfunds.com/rtw-biotech-opportunities-ltd">www.rtwfunds.com/rtw-biotech-opportunities-ltd</a> for more information.

\*\*\*\*\*

The information in this announcement may include forward-looking statements, which are based on the current expectations and projections about future events, and in certain cases can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue", "target", "believe" (or the negatives thereon) or other variations thereon or comparable terminology. These forward-looking statements, as well as those included in any related materials, are subject to risks, uncertainties and assumptions about the Company and/or its underlying investments, including, among other things, the development of the applicable entity's business, trends in its operating industry, expected use of financing proceeds and future capital expenditures and acquisitions. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not occur.

The information contained in this announcement is given at the date of its publication (unless otherwise marked). No reliance may be placed for any purpose whatsoever on the information or opinions contained in this announcement or on its completeness, accuracy or fairness.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact <a href="mailto:rns@lseg.com">rns@lseg.com</a> or visit <a href="www.ms.com">www.ms.com</a>.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <u>Privacy Policy</u>.

FND

**AGREAXEEDLSSFFA**